Publications (49) Publications de VANESA ANDRÉS GUERRERO

2024

  1. Enhancing the hypotensive effect of latanoprost by combining synthetic phosphatidylcholine liposomes with hyaluronic acid and osmoprotective agents

    Drug Delivery and Translational Research

  2. Smart biodegradable hydrogels: Drug-delivery platforms for treatment of chronic ophthalmic diseases affecting the back of the eye

    International Journal of Pharmaceutics, Vol. 649

2023

  1. A novel osmoprotective liposomal formulation from synthetic phospholipids to reduce in vitro hyperosmolar stress in dry eye treatments

    Journal of Liposome Research, Vol. 33, Núm. 2, pp. 117-128

  2. Desarrollo de microemulsiones de administración tópicaocular como plataforma para el tratamiento o prevención dela enfermedad de ojo seco

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  3. Desarrollo de una formulación antiglaucomatosa tópica a partir de una lágrima artificial

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  4. Long-acting hybrid microemulsion for the simultaneous treatment of glaucoma and ocular surface diseases

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  5. Microesferas biodegradables de liberación controlada de agentes antioxidantes y anti-inflamatorios como potencial terapia neuroprotectora para el glaucoma

    XVI Congreso SEFIG ( 16. 2023. Madrid): Libro de comunicaciones

  6. New trends towards glaucoma treatment: Topical osmoprotective microemulsions loaded with latanoprost

    Ocular Surface, Vol. 29, pp. 314-330

2022

  1. Cytokine profile in tear and aqueous humor of primary open-angle patients as a prognostic factor for trabeculectomy outcome

    European Journal of Ophthalmology, Vol. 32, Núm. 5, pp. 2994-3004

  2. Development of an osmoprotective microemulsion as a therapeutic platform for ocular surface protection

    International Journal of Pharmaceutics, Vol. 623

  3. Novel Osmoprotective DOPC-DMPC Liposomes Loaded with Antihypertensive Drugs as Potential Strategy for Glaucoma Treatment

    Pharmaceutics, Vol. 14, Núm. 7

  4. Nuevas terapias hipotensoras en el tratamiento del glaucoma: New hypotensive therapies in the treatment of glaucoma

    III Congreso Interdisciplinar de Jóvenes Investigadores 23 y 24 de septiembre de 2021

  5. Proinflammatory Cytokine Profile Differences between Primary Open-Angle and Pseudoexfoliative Glaucoma

    Ophthalmic research

  6. Validation of a Rapid and Easy-to-Apply Method to Simultaneously Quantify Co-Loaded Dexamethasone and Melatonin PLGA Microspheres by HPLC-UV: Encapsulation Efficiency and In Vitro Release

    Pharmaceutics, Vol. 14, Núm. 2

2021

  1. Combined hyperosmolarity and inflammatory conditions in stressed human corneal epithelial cells and macrophages to evaluate osmoprotective agents as potential DED treatments

    Experimental Eye Research, Vol. 211

  2. Dexamethasone PLGA Microspheres for Sub-Tenon Administration: Influence of Sterilization and Tolerance Studies

    Pharmaceutics, Vol. 13, Núm. 2, pp. 228

  3. Dexamethasone plga microspheres for sub-tenon administration: Influence of sterilization and tolerance studies

    Pharmaceutics, Vol. 13, Núm. 2, pp. 1-21

  4. Liposomes as vehicles for topical ophthalmic drug delivery and ocular surface protection

    Expert Opinion on Drug Delivery, Vol. 18, Núm. 7, pp. 819-847

  5. Microparticle Products for the Eye: Preformulation, Formulation, and Manufacturing Considerations

    AAPS Advances in the Pharmaceutical Sciences Series (Springer), pp. 381-407

  6. Posterior segment ophthalmic drug delivery: Role of muco-adhesion with a special focus on chitosan

    Pharmaceutics, Vol. 13, Núm. 10